ValuEngine upgraded shares of Cytosorbents (NASDAQ:CTSO) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning.
A number of other research firms also recently commented on CTSO. B. Riley set a $11.00 target price on shares of Cytosorbents and gave the company a buy rating in a research report on Friday, December 22nd. Maxim Group set a $12.00 price objective on shares of Cytosorbents and gave the stock a buy rating in a research report on Friday, March 9th. Cowen set a $9.00 price objective on shares of Cytosorbents and gave the stock a buy rating in a research report on Thursday, March 8th. Finally, HC Wainwright set a $14.00 price objective on shares of Cytosorbents and gave the stock a buy rating in a research report on Friday, March 9th. Six analysts have rated the stock with a buy rating, Cytosorbents presently has an average rating of Buy and a consensus target price of $11.05.
NASDAQ CTSO opened at $7.35 on Tuesday. The company has a current ratio of 2.64, a quick ratio of 2.54 and a debt-to-equity ratio of 0.58. The stock has a market cap of $218.09, a price-to-earnings ratio of -22.97 and a beta of -0.09. Cytosorbents has a one year low of $3.30 and a one year high of $8.25.
Cytosorbents (NASDAQ:CTSO) last posted its earnings results on Thursday, March 8th. The medical research company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). The business had revenue of $4.65 million for the quarter, compared to analysts’ expectations of $4.56 million. Cytosorbents had a negative net margin of 52.08% and a negative return on equity of 118.07%. equities research analysts expect that Cytosorbents will post -0.47 EPS for the current year.
In other news, CFO Kathleen P. Bloch sold 12,400 shares of Cytosorbents stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $7.75, for a total value of $96,100.00. Following the transaction, the chief financial officer now owns 241,038 shares of the company’s stock, valued at approximately $1,868,044.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Kathleen P. Bloch sold 11,176 shares of Cytosorbents stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $8.25, for a total transaction of $92,202.00. Following the completion of the transaction, the chief financial officer now directly owns 261,246 shares in the company, valued at approximately $2,155,279.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 67,080 shares of company stock worth $513,930. Insiders own 5.60% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN grew its position in shares of Cytosorbents by 182.3% in the 4th quarter. Wells Fargo & Company MN now owns 20,929 shares of the medical research company’s stock worth $136,000 after buying an additional 13,515 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in Cytosorbents in the 4th quarter worth approximately $146,000. Fortaleza Asset Management Inc. boosted its stake in Cytosorbents by 60.9% in the 4th quarter. Fortaleza Asset Management Inc. now owns 37,615 shares of the medical research company’s stock worth $244,000 after purchasing an additional 14,240 shares in the last quarter. Wealthcare Advisory Partners LLC acquired a new stake in Cytosorbents in the 3rd quarter worth approximately $365,000. Finally, BlueCrest Capital Management Ltd acquired a new stake in Cytosorbents in the 4th quarter worth approximately $396,000. 10.84% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/07/cytosorbents-ctso-raised-to-buy-at-valuengine.html.
CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.